Trial reportTranslational vision science & technology2024
Prediction of Long-Term Treatment Outcomes for Diabetic Macular Edema Using a Generative Adversarial Network.
Trial report in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Assessment of Deep Learning-Generated Ultra-Widefield Fluorescein Angiography From Fundus Images in Diabetic Retinopathy.Translational vision science & technology · 2026Article
- Efficacy and Safety of Anti-vascular Endothelial Growth Factor (VEGF) Agents in Diabetic Macular Edema.Cureus · 2026Review
- Diagnostic Accuracy of Artificial Intelligence in Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Recent advances in the study of Conbercept for diabetic macular edema.International journal of retina and vitreous · 2025Review
- Applications of generative adversarial networks in the diagnosis, prognosis, and treatment of ophthalmic diseases.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Artificial intelligence in proliferative diabetic retinopathy: advancing diagnosis, precision surgery, and anti-VEGF therapy optimization.Frontiers in medicine · 2025Review
- Based on TransRes-Pix2Pix network to generate the OBL image during SMILE surgery.Frontiers in cell and developmental biology · 2025Article
- Assessment of synthetic post-therapeutic OCT images using the generative adversarial network in patients with macular edema secondary to retinal vein occlusion.Frontiers in cell and developmental biology · 2025Article
- Construction of a predictive model for the efficacy of anti-VEGF therapy in macular edema patients based on OCT imaging: a retrospective study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose: The purpose of this study was to analyze optical coherence tomography (OCT) images of generative adversarial networks (GANs) for the prediction of diabetic macular edema after long-term treatment. Methods: Diabetic macular edema (DME) eyes (n = 327) underwent anti-vascular endothelial growth factor (VEGF) treatments every 4 weeks for 52 weeks from a randomized controlled trial (CRTH258B2305, KINGFISHER) were included. OCT B-scan images through the foveal center at weeks 0, 4, 12, and 52, fundus photography, and retinal thickness (RT) maps were collected. GAN models were trained to generate probable OCT images after treatment. Input for each model were comprised of either the baseline B-scan alone or combined with additional OCT, thickness map, or fundus images. Generated OCT B-scan images were compared with real week 52 images. Results: For 30 test images, 28, 29, 15, and 30 gradable OCT images were generated by CycleGAN, UNIT, Pix2PixHD, and RegGAN, respectively. In comparison with the real week 52, these GAN models showed positive predictive value (PPV), sensitivity, specificity, and kappa for residual fluid ranging from 0.500 to 0.889, 0.455 to 1.000, 0.357 to 0.857, and 0.537 to 0.929, respectively. For hard exudate (HE), they were ranging from 0.500 to 1.000, 0.545 to 0.900, 0.600 to 1.000, and 0.642 to 0.894, respectively. Models trained with week 4 and 12 B-scans as additional inputs to the baseline B-scan showed improved performance. Conclusions: GAN models could predict residual fluid and HE after long-term anti-VEGF treatment of DME. Translational Relevance: The implementation of this tool may help identify potential nonresponders after long-term treatment, thereby facilitating management planning for these eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.